Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
Hans P. Brunner-La Rocca, MD*,1,
David M. Kaye, MBBS, PhD, FRACP, FACC*,2,
Robyn L. Woods, PhD ,
Jacqueline Hastings, PhD* and
Murray D. Esler, MBBS, PhD, FRACP*
* Alfred and Baker Medical Unit, Baker Medical Research Institute, Alfred Hospital, Melbourne, Australia
Howard Florey Institute, University of Melbourne, Parkville, Australia

View larger version (25K):
[in a new window]
|
Figure 3 Scatter plots of changes in cardiac (top panel; lower BNP dose), whole-body (middle panel; lower BNP dose) and renal (bottom panel; higher BNP dose) NESP in relation to baseline levels in both groups. The "r" values are rank correlations. BNP = brain, or b-type, natriuretic peptide; CHF = congestive heart failure; NESP= norepinephrine spillover.
|
|
|